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ABSTRACT  50 
Metabolic syndrome after transplantation is a major concern following solid organ transplantation 51 
(SOT). The CREB-regulated transcription coactivator 2 (CRTC2) regulates glucose metabolism. The 52 
effect of CRTC2 polymorphisms on new-onset diabetes after transplantation (NODAT) was 53 
investigated in a discovery sample of SOT recipients (n1=197). Positive results were tested for 54 
replication in two samples from the Swiss Transplant Cohort Study (STCS, n2=1294 and n3=759). 55 
Obesity and other metabolic traits were also tested. Associations with metabolic traits in population-56 
based samples (n4=46’186, n5=123’865, n6>100,000) were finally analyzed. In the discovery sample, 57 
CRTC2 rs8450-AA genotype was associated with NODAT, fasting blood glucose and BMI 58 
(pcorrected<0.05). CRTC2 rs8450-AA genotype was associated with NODAT in the second STCS 59 
replication sample (OR=2.01, p=0.04). In the combined STCS replication samples, the effect of 60 
rs8450-AA genotype on NODAT was observed in patients having received SOT from a deceased 61 
donor and treated with tacrolimus (n=395, OR=2.08, p=0.02) and in non-kidney transplant recipients 62 
(OR=2.09, p=0.02). Moreover, rs8450-AA genotype was associated with overweight or obesity 63 
(n=1215, OR=1.56, p=0.02), new-onset hyperlipidemia (n=1007, OR=1.76, p=0.007), and lower 64 
HDL-cholesterol (n=1214, β=-0.08, p=0.001). In the population-based samples, a proxy of 65 
rs8450G>A was significantly associated with several metabolic abnormalities. CRTC2 rs8450G>A 66 
appears to play an important role in the high prevalence of metabolic traits observed in patients with 67 
SOT. A weak association with metabolic traits was also observed in the population-based samples.  68 
 69 
 70 
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Introduction 75 
The introduction of calcineurin inhibitors (CNIs) - cyclosporine (CSA) and tacrolimus (TAC) - in 76 
solid organ transplantation (SOT) has reduced the incidence of acute rejection episodes and improved 77 
short-term graft survival1, 2. However, both drugs are not devoid of metabolic complications, such as 78 
glucose intolerance, hypertension, and hyperlipidemia which can be very pronounced and have a 79 
detrimental impact on patients’ life quality, and increase the mortality risk due to cardiovascular 80 
events3. Indeed, cardiovascular disease is responsible for approximately 20-40% of non-graft-related 81 
death after the first post-transplantation year4-6.  82 
New onset diabetes mellitus after transplantation (NODAT) is a serious complication partly related to 83 
the use of CNIs, mainly TAC7, 8. It is also associated with increased cardiovascular events, infectious 84 
complications, and graft loss9, 10.There are several risk factors which increase the risk of NODAT in 85 
transplantation such as obesity, increased age, male sex, deceased donor, hepatitis C (HCV) status, 86 
acute rejection, and African-American or Hispanic descent9, 11. The identification of genetic factors 87 
involved in the development of NODAT may greatly benefit from a more detailed understanding of 88 
the complex metabolic pathways involved in glucose metabolism. Genome-wide association studies 89 
(GWAS) conducted to date explain only 10% of type 2 diabetes heritability and more diabetic 90 
susceptibility genes remain to be discovered (reviewed in 12 and 13). A recent GWAS investigating 91 
NODAT identified eight polymorphisms14. However, only one of these was replicated in another 92 
study15. Whereas GWAS have been extremely valuable, other approaches are needed to further 93 
understand the pathophysiology of NODAT. 94 
The cAMP-regulated transcriptional coactivator 2 (CRTC2), a transcriptional coactivator that 95 
promotes the transcription of genes targeted by the cAMP response element-binding protein16, is an 96 
interesting target protein in glucose metabolism. CRTC2 belongs to the CRTC family which 97 
comprises 2 other members, CRTC1 and CRTC317. CRTC1 is mainly expressed in the central nervous 98 
system and we recently showed an association between CRTC1 polymorphisms and obesity markers 99 
(body mass index (BMI) and fat mass) in psychiatric and population-based samples18, CRTC2 is 100 
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highly expressed in the thymus, and present in both T and B-lymphocytes17. It is also expressed in the 101 
liver and it plays a direct role during the fasting state in the induction of gluconeogenic genes16, It 102 
further enhances hepatic insulin signalling by stimulating expression of the insulin receptor substrate 103 
2 gene, thus triggering a feedback response that limits glucose output from the liver during fasting19, 104 
Calcineurin, the target of both TAC and CSA, plays an important role in the activation of CRTC220, 21. 105 
Overexpression of CRTC2 induced by a mutation at 2 regulatory sites rendered CRTC2 constitutively 106 
active in an animal model and permitted CRTC2-target gene activation even when calcineurin was 107 
inhibited by CNIs22. The authors of this study also showed that CRTC2 is required for β-cell function 108 
and proliferation and promoting this pathway could ameliorate symptoms of NODAT22. 109 
CRTC2 single nucleotide polymorphisms (SNPs) were previously investigated in two Asian 110 
populations and one coding SNP (R379C), with a very low minor allele frequency (MAF), was 111 
associated with type II diabetes23 and with lung cancer24. So far CRTC2 SNPs have not been 112 
investigated in other ethnic populations or with other phenotypes. In this work, we aimed to study the 113 
influence of CRTC2 SNPs on the incidence of NODAT in a sample of Caucasian SOT recipients, and 114 
positive results were then tested for replication in the Swiss transplant cohort Study (STCS). We also 115 
aimed to extend our analysis to obesity and other variables of the metabolic syndrome (MetS) 116 
following SOT. Finally, we aimed to test if the associations with MetS components could be found in 117 
general population-based samples (>100,000 subjects). 118 
 119 
Materials and Methods 120 
Discovery study sample: 121 
This study aimed initially to investigate the effect of genetic polymorphisms of drug metabolizing 122 
enzymes and/or transporters on the incidence of different post-transplant complications and on 123 
immunosuppressive doses and blood levels25, 26. For this study, a total of 197 patients were enrolled 124 
between 2003 and 2005 from the outpatient clinic of the Transplant Center of the University Hospital 125 
of Lausanne, Switzerland. Patients with functional graft for more than 12 months after transplantation 126 
were eligible to participate in the study. Data regarding patient’s age, gender, BMI, ethnic origin, 127 
donor’s age, HLA mismatch, duration of graft cold ischemia and delayed graft function were collected 128 
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retrospectively from patients’ medical files. Immunosuppressive regimens, doses and blood levels 129 
were obtained retrospectively at different time-points during the first year post-transplantation. The 130 
study was approved by the ethics committee of the University of Lausanne. Patients gave their written 131 
informed consent to participate in this pharmacogenetic study. Once included, venous blood samples 132 
were collected for DNA extraction and further genotyping analysis. 133 
For the present study, data were collected between October 2011 and April 2012 as related to the 134 
development of NODAT during the first 5 years following transplantation. Data regarding fasting 135 
blood glucose (FBG), glycated haemoglobin (HbA1c), 2hrs oral glucose tolerance test (OGTT), 136 
insulin and oral anti-diabetic treatment were collected retrospectively from the medical files at the 137 
time of transplantation, at 1, 3, 6, 9 and 12 month post-transplantation and at the yearly follow-up until 138 
5-year post-transplantation. NODAT was diagnosed if a patient needed anti-diabetic treatment (either 139 
insulin or oral anti-diabetic agents) for at least 6 months following transplantation or had several 140 
abnormal glucose profiles during the follow-up period that fulfil the criteria given by the WHO and 141 
ADA consensuses27, including FBG≥7.0 mmol/l (in ≥ two occasions) or 2 hours plasma glucose≥11.1 142 
mmol/l during OGTT 27 (even if not treated with anti-diabetic drugs). Patients who had diabetes or 143 
prediabetes before transplantation or were transplanted because of diabetic nephropathy were excluded 144 
from the present study.  145 
 146 
The Swiss Transplant Cohort Study (STCS): 147 
The STCS is an ongoing prospective multicenter cohort project (Basel, Bern, Genève, Lausanne, St. 148 
Gallen and Zurich), aiming at a nationwide comprehensive and structured data collection in all SOT 149 
recipients. All recipients of SOTs in Switzerland are prospectively registered since May 2008. 150 
Currently more than 3500 patients are included in the STCS. No particular eligibility or exclusion 151 
criteria exist for enrolment. After transplantation, all patients are mandatorily followed in their 152 
respective transplant centers. After baseline assessment, STCS follow-up assessments take place at 6-, 153 
12 months and yearly thereafter. Biological samples are collected in relation to the case at baseline, 154 
and at 6-, and the 12-month visits. Data regarding patient’s age, gender, BMI, blood pressure and lipid 155 
profiles (total cholesterol, HDL- and LDL-cholesterol) were available for all patients at the different 156 
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time-points of the STCS follow-up. Full description of this cohort is published elsewhere28, 29. For the 157 
first STCS replication sample, patients transplanted from May 2008 to 8th of May 2011 with a 158 
functional graft for at least 12 months after transplantation were included in the analyses (n=1294). 159 
NODAT was diagnosed if a patient needed anti-diabetic treatments following transplantation or if 160 
such new metabolic event was reported in their case report forms. For the second STCS replication 161 
sample, patients transplanted from 9th of May 2011 to May 2013 with a functional graft for at least 12 162 
months after transplantation were included in the analyses (n=759). For this second STCS replication 163 
sample, several random and FBG were available in the database, as well as HbA1c. Therefore, as for 164 
the discovery sample, NODAT was diagnosed if a patient needed anti-diabetic treatment (either 165 
insulin or oral anti-diabetic agents) or fulfilled the criteria given by the WHO and ADA consensuses 166 
mentioned earlier. For both STCS samples, patients who were diagnosed with diabetes or were 167 
prediabetics before transplantation or were transplanted because of diabetic nephropathy were 168 
excluded from the NODAT analyses. 169 
For the combined STCS sample, new-onset hypertension and new-onset hyperlipidemia were 170 
diagnosed if patients needed anti-hypertensive and hypolipidemic treatment post-SOT. Patients with 171 
previous hypertension or hyperlipidemia were excluded from the new-onset hypertension and new-172 
onset hyperlipidemia analyses, respectively. The study was approved by the ethics committee of their 173 
respective centers. Patients gave their written informed consent to participate in this pharmacogenetic 174 
study.  175 
Recipients younger than 18 years old and recipients with multiple organ transplantation were excluded 176 
from the whole analyses. If a patient received more than one transplantation during the inclusion 177 
period, only data from the first SOT was included in the analyses. 178 
For both the discovery and STCS samples, as abdominal obesity (waist circumference) was not 179 
available, BMI was used as a marker of obesity. 180 
 181 
Population based samples: 182 
We aimed to replicate results with MetS traits in several population-based samples: the Meta-Analyses 183 
of Glucose and Insulin-related traits Consortium (MAGIC)(n=46’186)30, Genetic Investigation of 184 
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ANtropometric Traits (GIANT) consortium (n=123’865)31-33, and Genome Wide Associations Scans 185 
for Total Cholesterol, HDL-C, LDL-C and triglycerides (n>100’000)34, 35.  More details are in the 186 
Supplementary Material. 187 
 188 
Polymorphism selection and genotyping: 189 
Two tagging SNPs within CRTC2 gene (rs8450G>A and rs12117078G>C) were selected using 190 
HapMap Genome Browser by limiting the search to SNPs with a MAF>5% in the Caucasian 191 
population and r2 cutoff of 0.8. Genotyping in the discovery study sample was done using Taqman 192 
allelic discrimination assays. Genetic analyses for the STCS replication samples were done using the 193 
fluorescence-based competitive allele-specific PCR technology (KASPar)36. More details are in the 194 
Supplementary Material. 195 
 196 
Statistical analysis: 197 
Detailed statistical methods are presented in the Supplementary Material. 198 
Discovery and STCS samples: 199 
We assessed the association of CRTC2 SNPs with MetS traits 1) by applying a logistic regression for 200 
binary outcomes adjusted for recipient’s age at transplantation and sex. Other variables identified 201 
through the univariate analysis (P<0.10) were also added as covariates in these models, 2) by using 202 
linear mixed models for continuous variables, and 3) by fitting a Generalized Additive Mixed Model 203 
(GAMM) to include a smooth trend for the response in time (allowing multiple observations for each 204 
patient) for non-linear continuous variables (BMI and FBG). 205 
For the discovery sample, the p-values of the models were adjusted for multiple comparisons using 206 
Bonferroni correction and the SNP that survived this correction was investigated in the STCS. 207 
Data for both the discovery and replications samples were analyzed using Stata 12 (StataCorp, College 208 
Station TX, USA) and R version 2.13.0 software (http://www.R-project.org).  209 
Population-based samples: 210 
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We analyzed the associations of CRTC2 SNP with different MetS traits using multivariate linear 211 
regression with allele dosage in which potential confounding factors such as age, sex, and smoking 212 
status were added as covariates. 213 
 214 
Results: 215 
Discovery and STCS replication samples: 216 
General characteristics of the discovery and STCS replication samples are presented in the 217 
Supplementary Material and Supplementary Tables 1 and 2. Supplementary Table 2 represents the 218 
global STCS sample without the exclusion of patients with previous history of diabetes or other 219 
metabolic abnormalities before transplantation.  220 
The distribution of CRTC2 genotypes in all studies did not deviate from the Hardy-Weinberg 221 
equilibrium (P>0.05) and the MAFs were similar to those reported in HapMap (Supplementary Table 222 
3). 223 
 224 
CRTC2 SNPs and NODAT, FBG, and BMI in the discovery study sample: 225 
Carriers of the CRTC2 rs8450-AA genotype showed increased risk of NODAT as compared to wild-226 
type GG genotype (odd ratio (OR)=6.91, 95%CI:1.52-31.36, pcorrected=0.02). An increased risk was 227 
also observed by analyzing the rs8450 SNP in a recessive model (Table 1). Neither cumulative 228 
prednisone dosages nor calcineurin inhibitors’ doses, trough levels or concentration/dose ratios tested 229 
at 2 time periods (at 1 month or at 12 months post-SOT) were associated with NODAT in the 230 
univariate analysis or when used in the multivariate model including CRTC2 SNPs and the other 231 
covariables (data not shown). 232 
FBG were also available at several time-points after SOT. By applying the GAMM model, increased 233 
FBG levels were found in patients with the CRTC2 rs8450-GA and AA genotypes (0.24 mmol/L, 234 
pcorrected=0.06 and 0.47 mmol/L, pcorrected=0.02, respectively) as compared to wild-type GG genotype. 235 
We observed an equal increased of FBG levels by analyzing the rs8450 SNP in dominant model 236 
(Table 1). 237 
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Patients with the CRTC2 rs8450-GA genotype showed a 1.36 kg/m2 increased BMI compared to the 238 
wild-type genotype (pcorrected=0.02). By analyzing the SNP in a dominant model, we observed a 239 
significant association between CRTC2 rs8450 and BMI (β=1.17, 95%CI:0.17-2.35, pcorrected=0.04). 240 
We observed no association between CRTC2 rs12117078G>C SNP and NODAT, FBG or BMI (Table 241 
1). 242 
CRTC2 SNP in the STCS replication samples: 243 
The CRTC2 rs8450G>A SNP that survived corrections for multiple testing in the discovery study 244 
sample was investigated in the STCS. Recessive models for this SNP are presented in the text and in 245 
Tables 2 and 3 while additive and dominant models regarding NODAT are presented in 246 
Supplementary Table 4. 247 
 248 
CRTC2 SNP and NODAT: 249 
In the univariate analyses, increased recipient’s age (p=0.0003), male sex (p=0.03), positive HCV 250 
status (p=0.003), deceased donor (p=0.04), treatment with TAC (p=0.001) and baseline BMI 251 
(p=0.0002) were among the non-genetic factors associated with an increased risk of NODAT and were 252 
used as covariates in the genetic models. In the first STCS replication samples, we observed a non-253 
significant association between rs8450G>A and NODAT (Table 2). However, by analyzing the SNP 254 
in the subgroup of patients having received SOT from a deceased donor and treated with TAC, a 255 
significant effect of the SNP was observed (n=281, OR=2.36, 95%CI:1.16-4.78, p=0.01)(Table 2). In 256 
the second replication sample (n=438), in which the diagnostic criteria for NODAT was the same as 257 
for the discovery sample, recipients carrying the rs8450-AA genotype showed a significant increased 258 
risk of NODAT (n=438, OR=2.01, 95%CI:1.03-3.91, p=0.04). In the combined STCS sample, the 259 
effect of the CRTC2 genotype was only observed in the subgroup of patients having received SOT 260 
from a deceased donor and treated with TAC (n=395, OR=2.08, 95%CI:1.15-3.74, p=0.02) (Table 2).  261 
 262 
 263 
 264 
10 
 
CRTC2 SNP and BMI, new-onset hypertension/ hyperlipidemia: 265 
We investigated the influence of CRTC2 rs8450G>A on BMI and on the incidence of new-onset 266 
hypertension/hyperlipidemia in the combined STCS sample. 267 
Increased recipient’s age (p<0.0001), male sex (p<0.0001) and type of transplanted organ (p<0.0001) 268 
were among the non-genetic factors associated with increased BMI in the univariate analyses and were 269 
used as covariates in the genetic models. BMI values were also dichotomized into normal versus 270 
overweight or obese (BMI≥25 kg/m2). At 12-months post-SOT, overweight or obese patients were 271 
more prevalent in the CRTC2 rs8450-AA genotype compared to the other genotypes (n=1215, 272 
OR=1.56, 95%CI:1.08-2.25, p=0.02). We observed the same association but with lower significance 273 
for the combined STCS sample at 6-months post-SOT (n=1389, OR=1.41, 95%CI:1.01-1.97, p=0.04), 274 
and a non-significant association with baseline BMI (n=1515, OR=1.20, 95%CI:0.87-1.65, p=0.27), 275 
suggesting that time post-SOT modulates the effect of the CRTC2 genotypes.  276 
By applying the GAMM model to test the association between BMI over time and CRTC2 rs8450G>A 277 
SNP (n=1625), patients with the CRTC2 rs8450-AA genotype showed a 0.47 kg/m2 (95%CI:0.11-1.02, 278 
p=0.01) increase in BMI compared to the other genotypes. 279 
We found no association between the CRTC2 rs8450G>A and the incidence of new-onset 280 
hypertension (Supplementary Material). On the other hand, carriers of the CRTC2 rs8450-AA 281 
genotype showed increased risk of new-onset hyperlipidemia as compared to the other genotypes 282 
(n=1007, OR=1.76, 95%CI:1.16-2.66, p=0.007). Additionally, patients with the CRTC2 rs8450-AA 283 
genotype also showed a significant decrease of HDL-Cholesterol levels in the combined STCS sample 284 
(n=1214, β= -0.08 mmol/L, p=0.001). CRTC2 rs8540G>A SNP was not associated with total 285 
cholesterol or with LDL-cholesterol blood levels in the combined STCS sample (data not shown). 286 
More details can be found in the Supplementary Material. 287 
 288 
CRTC2 SNP and MetS traits in kidney and non-kidney transplant recipients: 289 
Patients were dichotomized into kidney versus non-kidney transplant recipients (Table 3). The CRTC2 290 
rs8450-AA genotype was associated with significantly higher OR for NODAT in non-kidney 291 
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transplant recipients (n=409, OR=2.09, 95%CI:1.13-3.86, p=0.02), while the rs8450 AA-genotype was 292 
only associated with higher risk of new-onset hyperlipidemia in kidney transplant recipients (n=573, 293 
OR=1.95, 95%CI:1.14-3.15, p=0.01). 294 
 295 
Population-based samples: 296 
Several glycemic traits were available in the MAGIC study (Supplementary Table 5); each rs1572788 297 
C-allele (in complete linkage disequilibrium (LD) with rs8450 A-allele) increased FBG levels by 0.01 298 
mmol/l (n=46’186, p=0.004). Additionally, each rs1572788 C-allele decreased HOMA-B by 0.008% 299 
(n=46’186, p=0.03). No association was observed between rs1572788T>C and HOMA-IR or the 2 300 
hour OGTT.  301 
Decreased HDL-cholesterol and increased triglycerides were observed for each rs1572788 C-allele in 302 
the Genome Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides 303 
(n=96’908, β=-0.008, p=0.013 and n=93’562, β=0.009, p=0.004, respectively). We observed non-304 
significant associations for rs1572788T>C with total and LDL-cholesterol, as well as with obesity 305 
traits studied in the GIANT study, however, the direction of the effect is consistent with increased 306 
blood lipids and obesity with each rs1572788 C-allele (Supplementary Table 5). 307 
Discussions: 308 
The transcriptional co-activator (CRTC) family is implicated with energy expenditure (CRTC1 and 309 
CRTC3)37, 38 and glucose metabolism (CRTC2)16 in animal models. In the present study, we aimed to 310 
study the effect of CRTC2 SNPs on the development of diabetes in SOT recipients, a population at 311 
high risk of developing metabolic abnormalities, and in population-based samples. We also extended 312 
our analyses to investigate obesity and other metabolic traits. The CRTC2 rs8450-AA genotype was 313 
associated with increased risk of NODAT, increased FBG, and BMI in a sample of 156 patients with 314 
SOT. Results on NODAT were replicated only in the second STCS replication sample (n=438), while 315 
in the first and the combined STCS replication samples, the SNP only showed significant influence in 316 
the population at higher risk of developing NODAT, mainly in recipients having received a graft from 317 
a deceased donor and treated with TAC. We also observed a significant association for BMI in the 318 
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STCS replication sample; overweight and obesity were also more frequent in patients carrying the 319 
rs8450-AA genotype at 12 months post-SOT. CRTC2 rs8450G>A was also associated with increased 320 
risk of new-onset hyperlipidemia following SOT and with lower HDL-cholesterol blood levels. 321 
Furthermore, we also found the increased risk of the C-allele of rs1572788 (in complete LD with 322 
rs8450 A-allele) on diabetic and lipidemic traits in two large population-based samples (MAGIC and 323 
GWAS for Total Cholesterol, HDL-C, LDL-C and triglycerides, respectively), and a consistent 324 
direction even though non-significant between rs1572788T>C and obesity traits in the GIANT study. 325 
CRTC2 rs8450G>A was associated with NODAT in the total discovery sample and only in the second 326 
STCS replication sample, but not in the total STCS sample in which a significant association was 327 
observed only in the subgroup of patients at higher risk of developing NODAT. This could partly be 328 
explained by the difference of NODAT diagnostic criteria, which is only based on anti-diabetic 329 
treatment in the first STCS replication sample. Another explanation could be the high percentage of 330 
patients receiving an organ from a living donor in the first STCS replication sample (28%, 331 
Supplementary Table 2) compared to only 11.5% in the discovery sample (Supplementary Table 1). 332 
Deceased donor is a common risk factor of NODAT11 and the impact of the SNP seems to be more 333 
prominent in the groups at higher risk of developing MetS traits. Additionally, when differentiating 334 
kidney and non-kidney transplant recipients (Table 3), we observed a significant association between 335 
the CRTC2 rs8450-AA genotype and NODAT in non-kidney transplant recipients. The percentage of 336 
non-kidney transplant recipients was higher in the second STCS replication sample compared to the 337 
first STCS sample (Supplementary Table 2) and it should be noted that kidney transplant recipients 338 
had higher percentages of living donors compared to non-kidney transplant recipients (43% vs. 2% 339 
respectively). Moreover, kidney transplant recipients usually have obesity and other metabolic 340 
problems already before transplantation compared to other solid organ recipients, which could explain 341 
the differential effect of the SNP depending on the type of the transplanted organ. Interestingly, in 342 
both the discovery and the combined STCS samples, the effect of the SNP was stronger in NODAT 343 
cases developed after the first year post-SOT (data not shown), It maybe that the effect of the CRTC2 344 
SNP on NODAT is more important in the long-term, but this remains to be further studied. 345 
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In the GWAS literature, CRTC2 SNPs were not found to be associated with diabetes, obesity or 346 
hyperlipidemia. On the other hand, by testing the individual effect of CRTC2 rs1572788T>C SNP on 347 
diabetic and lipidemic traits in two population-based samples, a significant effect was observed, even 348 
though this effect is very weak and the variance explained by the SNP is very small (Supplementary 349 
Table 5) and could thus not be detected by GWAS. However, patients with SOT is a population at risk 350 
of developing MetS traits, because of the disease itself and/or the immunosuppressive medications, 351 
both can act as an important trigger, unmasking different genetic factors. So in this at risk population, 352 
the effect of CRTC2 SNP was more pronounced, even in much smaller sample sizes compared to 353 
population-based samples. Additionally, in the GWAS of NODAT14, CRTC2 SNPs did not reach 354 
genome-wide level of significance. Moreover, most of the SNPs retained in this GWAS were not 355 
replicated in another study with NODAT15. In fact, both GWAS and candidate gene studies are 356 
important gene association approaches and both are subject to the same artifacts of spurious 357 
association findings. Depending on the methodology of these studies (sample size, definition of the 358 
phenotypes, MAF of the SNPs, corrections for multiple testing, etc…), discordances between both 359 
approaches could be seen. GWAS relies on indirect association to locate a disease-causing variant 360 
while candidate gene approach relies on an a priori hypothesis to identify this disease-causing variant. 361 
For all of these reasons, replication of positive finding in either approach is of utmost importance to 362 
validate the results.   363 
The functional activity of this SNP, in the regulatory 3’UTR, is unknown and data from 1000 364 
Genomes39 showed that 78 SNPs in the CRTC2 gene region are in high LD (r2 threshold≥0.8) with 365 
rs8450G>A. We used the RegulomeDB database that annotates SNPs with known and predicted 366 
regulatory elements in the intergenic regions of the H. sapiens genome40. This database reveals known 367 
and predicted regulatory DNA elements including regions of DNAase hypersensitivity, binding sites 368 
of transcription factors, and promoter regions that have been biochemically characterized to regulation 369 
transcription. Source of these data include public datasets from GEO, the ENCODE project, and 370 
published literature. Regarding CRTC2 rs8450G>A, several of these proxy SNPs (e.g. rs6680140 with 371 
r2=1) show cis-eQTL effect on the expression of CRTC2 and fall into the autoimmune regulatory 372 
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(AIRE) motif, influence the binding of several proteins (JUN, CREBBP and ELF1), and has several 373 
histone marks (H3k09me3, H4k20me1, etc.). Altogether, these data suggest that the SNP might have a 374 
regulatory function. 375 
Interestingly, among the analyzed clinical factors, treatment with corticosteroids was not associated 376 
with NODAT, neither in the discovery cohort nor in the STCS sample. However, in our samples most 377 
of the patients were treated with corticosteroids so it is difficult to draw major conclusions. On the 378 
other hand, the cumulative corticosteroids dosages and the duration of therapy rather than the simple 379 
corticosteroids administration could be the most influencing factors. In our discovery sample, the 380 
cumulative dosages of corticosteroids at the first year post-transplantation were not associated with 381 
NODAT outcome. In the literature, several studies did not find any influence of cumulative 382 
corticosteroid dosages on the appearance of NODAT41-45. The current lower dosages of corticosteroids 383 
used in different immunosuppressive regimens could contribute to the negative association with 384 
NODAT appearance in our study. 385 
This study has several limitations and strengths. Random and FBG levels were only available in the 386 
second STCS replication sample and the diagnosis of NODAT in the first STCS replication sample 387 
was only based on anti-diabetic treatments post-SOT. The genotype of the rs8450G>A SNP of the 388 
liver transplant donors is unknown, therefore the significant effect of the SNP on NODAT found in 389 
non-kidney transplant recipients, in which nearly half of them are liver transplant recipients, should be 390 
interpreted with caution.  However, CRTC2 is expressed in different tissues and is implicated in 391 
glucose regulation through different mechanisms (gluconeogenesis, insulin signaling and beta-cell 392 
survival16, 19, 22) which could highlight the importance of recipient CRTC2 genotype even in liver 393 
transplant recipients. Additionally, by excluding patients with liver transplantation from the non-394 
kidney transplant recipients’ analyses, a significant association between the CRTC2 SNP and NODAT 395 
is still observed (data not shown). The present results do not allow the determination of whether the 396 
rs8450G>A SNP is the causative variant or merely a proxy of one or more yet unidentified variants. 397 
Despite the possible regulatory functions proposed by the RegulomeDB database, further studies are 398 
needed to elucidate which precise mechanisms underlie the observed association. This study included 399 
15 
 
people of Caucasian origin and results cannot be generalized to other ethnic groups. On the other hand, 400 
the fact that the results were replicated in two independent samples with SOT and in large population-401 
based samples, the latter used as a proof of concept of the effect of the polymorphism, strengthens the 402 
validity of our data.  403 
In conclusion, our results suggest that variations in CRTC2 play an important role in the high 404 
prevalence of MetS complications observed in patients with SOT. Besides, by studying CRTC2 SNPs 405 
in population-based samples, we still observed a weak yet significant association, thereby suggesting 406 
that the effect of CRTC2 variations is more important in population at risk of developing different 407 
MetS traits than in the general population. This is the first study showing the importance of CRTC2 408 
variations with NODAT and other MetS traits in patients with SOT. The assessment of the major risk 409 
gene variants would allow predicting vulnerability for developing Mets phenotypes and thus adapt the 410 
immunosuppressive treatment from the beginning by genotyping the patients before transplantation. In 411 
the long-term, these patients could benefit from individualized immunosuppressive regimens adapted 412 
to their genetics and environment. 413 
 414 
 415 
 416 
 417 
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 420 
 421 
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Table 1 Association between CRTC2 SNPs and NODAT, blood glucose levels and BMI in patients with solid organ transplantation from the 
discovery study sample: 
            NODAT 
          (n=156)  
                   FBG 
                 (n=156)  
                    BMI 
                 (n=156) 
SNP OR (95% CI) P corrected  
Difference (mmol/L) 
compared to wild-type (ref)  
(95% CI) 
P 
corrected  
Difference (kg/m2) compared 
to wild-type (ref)  
(95% CI) 
P 
corrected 
CRTC2 rs8450 
GG ref   ref   ref  
GA 1.81 (0.71 - 4.61) 0.46  0.24 (-0.00 - 0.49) 0.06  1.36 (0.28- 2.42) 0.02 
AA 6.91 (1.52 - 31.36) 0.02  0.47 (0.07 - 0.86) 0.02  0.37 (-1.38 - 2.06) 0.76 
Dominant 2.32 (0.96 - 5.63) 0.12  0.28 (0.05 - 0.51) 0.02  1.17 (0.17 - 2.35) 0.04 
Recessive 5.11 (1.24 - 21.03) 0.04  0.36 (-0.03 - 0.74) 0.06  -0.24 (-2.33 - 1.68) 0.80 
CRTC2 rs12117078 
GG ref   ref   ref  
GC & CC    0.36 (0.11 - 1.16) 0.18  -0.07 (-0.40 - 0.24) 0.70  0.24 (-1.41 - 1.62) 0.78 
NODAT: New-onset diabetes after transplantation, FBG: Fasting blood glucose, OR: odd ratio, CI: confidence interval, BMI: body mass index. 
Regarding NODAT and blood glucose levels analyses: P values were adjusted for age of recipient at transplantation, sex of the recipient and 
baseline BMI and type of calcineurin inhibitor. 
Regarding BMI analyses: P values were adjusted for age of recipient at transplantation, sex of the recipient and type of calcineurin inhibitor. 
24 
 
Table 2: Association between CRTC2 rs8450 SNP in a recessive model and NODAT in the first, second and 
combined population of STCS and in different subgroups at risk of NODAT: 
CRTC2 rs8450  GG&GA (n)                      AA 
 N total           NODAT OR (95% CI) P value 
First STCS replication sample§:     
Total 711 Ref (n=623) 1.02 (0.62 - 1.70) 0.93 
Treatment with TAC & deceased donor 281 Ref (n=244) 2.36 (1.16 - 4.78) 0.01 
Second STCS replication sample§:     
Total 438 Ref (n=385) 2.01 (1.03 - 3.91) 0.04 
Combined STCS replication sample§:     
Total 1149 Ref (n=1008) 1.25 (0.84 - 1.87) 0.26 
Treatment with TAC & deceased donor 395 Ref (n=340) 2.08 (1.15 - 3.74) 0.02 
§Excluding patients with previous history of diabetes before transplantation 
NODAT: New-onset diabetes after transplantation, TAC: tacrolimus, OR: odd ratio, CI: confidence interval 
P values were adjusted (when appropriate) for age of recipient at transplantation, sex of the recipient, 
hepatitis C status, baseline BMI,  type of calcineurin inhibitor and type of donor. 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Table 3: Association between CRTC2 rs8450 SNP and MetS traits in all kidney and non-kidney transplant 
recipients in the combined STCS sample 
  Kidney transplant recipients  Non-kidney transplant recipients 
  n OR 
(95% CI) for rs8450-AA  
p-value  n OR 
(95% CI) for rs8450-AA 
p-value  
          
NODAT  740 0.87 (0.50 - 1.52) 0.62  409 2.09 (1.13 - 3.86) 0.02  
          
BMI≥25 kg/m2 at 
12months post 
SOT 
 761 1.59 (0.98 - 2.58) 0.06  454 1.52 (0.84 - 2.75) 0.17  
          
New-onset 
hyperlipidemia 
 573 1.95 (1.14 - 3.15) 0.01  434 1.73 (0.84 - 3.56) 0.14  
          
New-onset 
hypertension 
 146 1.64 (0.43 - 6.30) 0.47  345 1.44 (0.75 - 2.78) 0.27  
          
OR: odd ratio, CI: confidence interval 
NODAT: New-onset diabetes after transplantation, BMI: body mass index 
For NODAT analyses: P values were adjusted for age of recipient at transplantation, sex of the recipient, 
baseline BMI,  type of calcineurin inhibitor and type of donor. 
For BMI analyses: P values were adjusted for age of recipient at transplantation and sex of the recipient. 
For new-onset hyperlipidemia analyses: P values were adjusted for age of recipient at transplantation, sex of 
the recipient, baseline BMI, the type of calcineurin inhibitor and treatment with corticosteroids. 
For new-onset hypertension analyses: P values were adjusted for age of recipient at transplantation and sex 
of the recipient, treatment with corticosteroids, the type of calcineurin inhibitor and type of donor. 
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Materials and Methods 27 
Population based samples: 28 
The Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) 29 
MAGIC is a large-scale meta-analyses of genome-wide data for continuous diabetes-related traits in 30 
participants without diabetes 1. Meta-analyses of ~2.5 million directly genotyped or imputed 31 
autosomal single nucleotide polymorphisms (SNPs) were performed from genome-wide association 32 
studies (GWAS). These cohorts include up to 46’186 non-diabetic participants of European descent 33 
informative for FBG, the surrogate estimates of beta-cell function (HOMA-B) and insulin resistance 34 
(HOMA-IR) derived from fasting variables by homeostasis model assessment and up to 15’234 non-35 
diabetic individuals informative for 2 hour oral glucose tolerance test (OGTT) 2. 36 
 37 
Genetic Investigation of ANtropometric Traits (GIANT) consortium 38 
The GIANT consortium performed a meta-analysis of GWAS data with a discovery set of 123’865 39 
individuals of European ancestry from 46 studies for height 3, BMI4 and waist-to hip ratio 5.  40 
 41 
Genome Wide Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides 42 
Data on lipid traits have been downloaded from “Genome Wide Associations Scans for Total 43 
Cholesterol, HDL-C, LDL-C and triglycerides” website 6, 7 which is a meta-analysis of 46 lipid 44 
GWASs. These studies together comprise >100,000 individuals of European descent (maximum 45 
sample size 100,184 for Total Cholesterol, 95,454 for LDL-C, 99,900 for HDL-C and 96,598 for 46 
triglycerides), ascertained in the United States, Europe or Australia. 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
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Polymorphism selection and genotyping: 55 
Polymorphisms within CRTC2 were selected using HapMap Genome Browser (release 28)8. Two 56 
tagging SNPs were found by limiting the search to SNPs within CRTC2 gene ± 1kb with a minor 57 
allele frequency > 5% in the Caucasian population and r2 cutoff of 0.8: rs8450G>A within the 3’UTR 58 
and the intronic rs12117078G>C SNP.  59 
Genotyping of these 2 SNPS for the discovery study sample was done using Taqman allelic 60 
discrimination assays (ABI PRISM 7000 Sequence Detection System; Applied Biosystems, Rotkreuz, 61 
Switzerland) after genomic DNA extraction from whole blood. Life technologies Taqman genotyping 62 
assays C__8722376_10 and C__30997814_10 were used for CRTC2 rs8450G>A and 63 
rs12117078G>C SNPs, respectively. Genotyping were performed in the Unit of Pharmacogenetics 64 
and Clinical Psychopharmacology, in Lausanne, Switzerland. 65 
Genetic analyses for the first STCS replication sample were performed by KBioscience Institute in 66 
United Kingdom using the novel fluorescence-based competitive allele-specific PCR technology 67 
(KASP™). Details about this technology are available at 68 
http://www.lgcgenomics.com/genotyping/kasp-genotyping-chemistry/.  69 
Genetic analyses for the second STCS replication sample were also performed using the KASP™ 70 
technology on ABI 7500 Fast real-time thermocycler (Applied Biosystems). Genotyping were 71 
performed in the service of infectious disease in Lausanne University Hospital, Lausanne, 72 
Switzerland, according to manufacturer’s protocols (LGC Genomics, UK). The KASP primers were 73 
designed by Kraken™ assay design and workflow management software and further validated by 74 
manufacturer (LGC Genomics, UK). Automated allele calling was performed using SDS software 75 
according to standard protocols (Applied Biosystems). The following primers were used for CRTC2 76 
rs8450G>A genotyping in this sample: primer allele FAM: ACCCCTAGGCATCCGGAAAAG, 77 
primer allele HEX: CACCCCTAGGCATCCGGAAAAA and common primer 78 
GGGTAGAGGGGAGCCCTGGAA. 79 
 80 
 81 
 82 
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Statistical analysis: 83 
Quantitative data are presented as median and range unless otherwise mentioned, while qualitative 84 
data are presented as frequency and percentage. For association studies, the chi-square (Chi2) test or 85 
the Fisher exact test for binomial variables were used. Differences in allele and genotype frequencies 86 
as well as deviation from Hardy-Weinberg equilibrium were assessed using Chi2 test.  87 
 88 
Discovery study sample: 89 
For NODAT analyses, logistic regression was applied adjusted for recipient’s age at transplantation, 90 
sex, BMI at baseline and type of CNIs. Due to nonlinearity of our models and the absence of any 91 
linear transformation, the association between CRTC2 SNPs with BMI and FBG levels was assessed 92 
by fitting a Generalized Additive Mixed Model (GAMM) 9, 10 to allow a smooth trend for the response 93 
in time based on multiple observations for each patient (using a thin plate regression spline basis) 94 
adjusting for recipient’s age at transplantation, sex, and type of CNIs (antidiabetic treatments for FBG 95 
analyses). GAMMs were fitted using the mgcv package of R (settings were fixed at package defaults). 96 
In order to be more conservative, the uncertainty of estimated parameters were assessed by 1000 97 
bootstraps 11 at the subject level and results were similar with those gained by 10’000 bootstraps. 98 
Due to the small number of subjects being homozygous for the variant allele of CRTC2 99 
rs12117078G>C, this SNP was analyzed in a dominant model.  100 
 101 
Replication samples (STCS): 102 
For the statistical analyses of NODAT, new-onset hypertension, new-onset hyperlipidemia, and 103 
overweight or obese, logistic regression models were applied adjusted for recipient’s age at 104 
transplantation and sex. Other variables identified through the univariate analysis (P<0.10) were also 105 
added as covariates in these models. GAMM models were applied for BMI and HDL-cholesterol 106 
analyses in the STCS sample, as both models were not linear. Linear mixed models were used for 107 
systolic and diastolic blood pressure analyses and for blood total cholesterol and LDL-cholesterol 108 
analyses. In addition to recipient’s age at transplantation, sex, BMI at baseline and type of CNIs, blood 109 
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pressure models and lipid models were also adjusted for antihypertensive and hypolipidemic drugs 110 
intake, respectively.  111 
 112 
Population-based samples: 113 
The associations of CRTC2 SNP with different MetS traits were analyzed using multivariate linear 114 
regression with allele dosage in which potential confounding factors such as age, sex and smoking 115 
status were added as covariates. FBG, OGTT, the surrogate estimates of beta-cell function (HOMA-B) 116 
and insulin resistance (HOMA-IR) were analyzed in the MAGIC study. BMI, waist circumference and 117 
waist-to hip ratio were the only adiposity traits analyzed by the GIANT Consortium. Triglycerides, 118 
total cholesterol, HDL-cholesterol and LDL-cholesterol were analyzed in the “Genome Wide 119 
Associations Scans for Total Cholesterol, HDL-C, LDL-C and triglycerides” study. 120 
 121 
Results: 122 
General characteristics of the discovery sample 123 
Among the 197 patients included in the initial study, 17 patients were excluded because they were 124 
diagnosed with diabetes before transplantation, 11 patients had no follow-up data in their medical 125 
files, 2 patients did not sign consents for MetS-related genetic analysis, 4 patients dropped-out from 126 
the study and 7 were non-Caucasians. Finally, 156 Caucasian patients were included in the current 127 
study, 65% were kidney transplant recipients. The mean age at transplantation was 47.8 ± 11 years, 128 
61% were male and the mean BMI pre-transplant was 24 ± 4 kg/m2. During the five years of follow-up 129 
post-transplantation, NODAT occurred in 45 (28.9%) patients. Most NODAT cases (67%) occurred 130 
during the 1st year after transplantation. Most of the patients were treated with CSA (n=102, 65%), 131 
while 35% (n=54) were treated with TAC. As expected, NODAT was higher in the TAC-treated group 132 
compared to CSA12 (46.3 vs. 19.6 % respectively). Full characteristics of our population and their 133 
distribution between NODAT and non-NODAT patients are presented in Supplementary Table 1. 134 
Recipient age (p=0.002), male sex (p=0.05), donor age (p=0.04), baseline BMI (p=0.0003) and the 135 
type of CNIs (p<0.001) were significantly different between patients with and without NODAT 136 
(Supplementary Table 1). 137 
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 138 
General characteristics of the replication sample (STCS): 139 
Overall, 1294 patients from the first STCS replication sample received a SOT from May 2008 until 140 
May 2011, among them 1219 patients had both the clinical data and the genetic material available and 141 
were included in the current study. By excluding patients younger than 18 years old and patients with 142 
multiple organ transplantation, 958 patients remained and included in the analysis. The mean age at 143 
transplantation was 52.3 ± 13 years, 66% were male and pre-transplant BMI was 24.6 kg/m2 144 
(range:13.7-41.2). During the follow-up period post-transplantation, NODAT, new-onset HTN and 145 
new-onset hyperlipidemia occurred in 27.4%, 67.6% and 33.1% of the patients, respectively. Among 146 
the patients included in the second STCS replication sample (n=759) with both clinical and genetic 147 
data and by excluding patients younger than 18 years old and patients with multiple organ 148 
transplantation, 667 remained and were included in the analysis. Lower incidence of NODAT, new-149 
onset HTN and new-onset hyperlipidemia were observed in this sample, which could be explained by 150 
the shorter follow-up duration compared to the first STCS replication sample (Supplementary Table 151 
2). Full description of the first, second and combined STCS samples are presented in Supplementary 152 
Table 2. All patients from both STCS samples were of Caucasian origin.   153 
 154 
CRTC2 SNP and new-onset hypertension in the STCS: 155 
Among the non-genetic factors, type of calcineurin inhibitor (p<0.0001), type of transplanted organ 156 
(p<0.0001), treatment with corticosteroids (p<0.0001) and type of donor (p=0.02) were associated 157 
with increased risk of new-onset hypertension after SOT in the univariate analyses and were used as 158 
covariates in the genetic models. A non-significant association was observed between CRTC2 159 
rs8450G>A and new-onset hypertension, except for patients carrying the rs8450-GA genotype which 160 
showed a protective effect against new-onset hypertension (n=491, OR=0.62, 95%CI: 0.42 - 0.94, 161 
p=0.02) compared to wild type genotype. 162 
CRTC2 rs8450G>A SNP was not associated with systolic or diastolic blood pressure levels (data not 163 
shown). 164 
 165 
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 166 
CRTC2 SNP and new-onset hyperlipidemia in the STCS: 167 
Among the non-genetic factors, increased recipient’s age (p=0.003), baseline BMI (p=0.006), type of 168 
calcineurin inhibitor (p=0.005) and treatment with corticosteroids (p<0.0001) were associated with 169 
increased risk of new-onset hyperlipidemia after SOT in the univariate analyses and were used as 170 
covariates in the genetic models. 171 
 172 
 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
 184 
 185 
 186 
 187 
 188 
 189 
 190 
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   Supplementary Table 1: Clinical characteristics of the discovery study sample: 191 
Characteristic Total Non-NODAT NODAT p-value 
Recipient age at transplantation (years), 
median  (range) 
48 (22-68) 46 (22-68) 53 (28-68) 0.002 
Recipients sex (Males) [%] 60.9 55.9 73.3 0.05 
Living donor  [%] 11.5 11.7 11.1 0.92 
Donor age (years), median  (range) 43.5 (10-73) 41 (10-73) 48 (13-69) 0.04 
Donor sex (Males) [%] 56.8 63.2 54.8 0.06 
Organ, n [%] 
           lung 
           kidney  
           liver  
17 (10.9) 
102(65.4) 
37(23.7) 
 
10 (9.0)  
75 (67.6) 
26 (23.4) 
 
7 (15.6) 
27(60.0) 
11 (24.4) 
 
0.46 
BMI pre-transplant (kg/m2), median  
(range) 
23.5 (15.8-37.3) 22.3 (15.8-36.2) 26.4 (18.8-37.3) 0.0003 
BMI 5 year follow-up (kg/m2), median  
(range) 
26.0 (16.7-43.6) 25.5 (16.7-43.6) 27.1 (19.9-42.3) 0.10 
Recipient CMV infection  (R+) [%] 49.3 52.5 42.2 0.25 
Donor CMV infection (D+) [%] 61.5 59.2 66.7 0.39 
Recipient and Donor CMV infection (R+/D+) 
[%] 
27.6 27.0 28.9 0.81 
Calcineurin inhibitors, n  [%] 
                  TAC 
                  CSA  
54 (34.6) 
102 (65.4) 
 
29 (26.1) 
82 (73.9) 
 
25 (55.6) 
20 (44.4) 
 
<0.001 
First transplantation [%] 80.1 77.5 86.7 0.19 
Acute rejection episode during first year  
post-transplant [%] 
47.4 47.2 47.7 0.96 
NODAT: New-onset diabetes after transplantation, BMI: body mass index, CMV: cytomegalovirus, R: recipient, D: 
Donor, TAC: Tacrolimus, CSA: Cyclosporine.  
 192 
 193 
 194 
195 
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Supplementary Table 2: Clinical characteristics of STCS§ 196 
Characteristic 
First STCS 
replication sample 
(n=958) 
Second STCS 
replication sample 
(n=667) 
combined STCS replication 
sample 
(n=1625) 
Recipient age at transplantation (years), 
median  (range) 
55 (18-79) 55 (79) 55 (18-79) 
Recipients sex (Males) [%] 66.2 64.6 65.5 
Period of follow-up (months), median  (range) 12 (0-60) 6 (0-48) 6 (0-60) 
Living donor  [%] 28.7 24.0 26.7 
Donor age (years) 53 (1-86) 55 (1-88) 53 (1-88) 
Donor sex (Males) [%] 53.5 53.4 53.4 
Organ, n [%] 
          Kidney 
          Liver  
          Lung 
          Heart 
          Islets and pancreas£ 
          
       624 (65.1) 
158 (16.5) 
94 (9.8)  
65 (6.8) 
17 (1.8) 
 
360 (54.0) 
142 (21.3) 
97 (14.5) 
57 (8.6) 
11 (1.6) 
 
984 (60.5) 
300 (18.5) 
191 (11.8) 
122 (7.5) 
28 (1.7) 
BMI pre-transplant (kg/m2), median  (range) 24.6 (13.7-41.2) 24.9 (13.4-43.5) 24.8 (13.4-43.5) 
BMI 1 year follow-up (kg/m2), median  (range) 25.3 (15.4-44.6) 24.8 (13.7-41.7) 25.2 (13.7-44.6) 
Recipient CMV infection  (R+) [%] 57.5 59.5 58.2 
Donor CMV infection (D+) [%] 53.4 58.4 56.2 
Recipient and Donor CMV infection (R+/D+) [%] 33.0 36.3 34.3 
Calcineurin inhibitors,  [%] 
                  TAC 
                  CSA  
                  None 
 
65.5 
26.7 
7.8 
 
67.1 
26.1 
6.8 
 
66.3 
26.4 
7.3 
Incidence of NODAT [%] 27.4 18.7 24.4 
Incidence of New hypertension [%] 67.6 32.8 53.6 
Incidence of New hyperlipidemia [%] 33.1 13.8 26.6 
§patients included in this table represent the global STCS sample with the clinical data available for the analyses 
without the exclusion of patients with diabetes, hypertension or hyperlipidemia before transplantation. 
£These patients had type I diabetes mellitus as an indication for transplantation and were excluded from NODAT analysis.  
Abbreviations: BMI: body mass index, CMV: cytomegalovirus, R: recipient, D : Donor, TAC: Tacrolimus, CSA: 
Cyclosporine, NODAT: New-onset diabetes after transplantation, New hypertension: new onset hypertension 
after transplantation, New hyperlipidemia: new onset hyperlipidemia after transplantation. 
 
 197 
 198 
 199 
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Supplementary Table 3: Genotype frequencies in the discovery sample and in the first, the 200 
second and the combined STCS samples. Hardy-Weinberg equilibrium and a comparison 201 
between the observed minor allele frequency and HapMap minor allele frequency in the 202 
Caucasian population. 203 
  SNP CRTC2 SNPs Frequencies n (%)  
Hardy-Weinberg 
Equilibrium 
(p-value) 
MAF 
observed HapMap 
Discovery sample (n=156) 
    
rs8450 GG GA AA 0.87 0.30 0.30 
 
78 (50.0) 64 (41.0) 14 (9.0)    
rs12117078 GG GC CC 0.75 0.10 0.10 
 
126 (80.8) 28 (17.9) 2 (1.3)    
STCS  
  
   
rs8450 GG GA AA 
 
 0.30 
First STCS 
sample 
(n=949)§ 
408 (43.0) 429 (44.2) 112 (11.8) 0.96 0.34 
 
second STCS 
sample 
(n=667) 
281 (42.1) 302 (45.3) 84 (12.6) 0.84 0.35 
 
Combined 
STCS sample 
(n=1616) 
689 (42.7) 731 (45.2) 196 (12.1) 0.92 0.35 
 
§9 missing genotypes for this sample.     204 
MAF: minor allele frequency.  205 
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Supplementary Table 4: Association between CRTC2 rs8450 SNP and NODAT in total population of STCS in different subgroups at risk 
of NODAT: 
  Additive model  Dominant model 
CRTC2 rs8450  GG                 GA                   AA  GG                  GA&AA 
 
N   NODAT OR 
(95% CI) 
p-value  NODAT OR 
 (95% CI) 
p-value    NODAT OR  
(95% CI) 
p-value 
First STCS replication sample:        
Total 711 ref 0.97 (0.68 - 1.38) 0.85 1.01 (0.59 - 1.73) 0.98  ref 0.97 (0.70 - 1.37) 0.88 
Treatment with TAC & 
deceased donor 
281 ref 1.08 (0.63 - 1.85) 0.79 2.45 (1.14 - 5.26) 0.02  ref 1.31 (0.79 - 2.17) 0.30 
           
Second STCS replication sample:      
Total 438 Ref  0.81 (0.47 - 1.40) 0.46 1.80 (0.88 - 3.71) 0.11  ref 0.99 (0.60 - 1.62) 0.96 
           
Combined STCS replication sample:        
Total 1149 ref 0.89 (0.66 - 1.20) 0.44 1.18 (0.76 - 1.81) 0.46  ref 0.95 (0.72 - 1.25) 0.70 
Treatment with TAC & 
deceased donor  
395 ref  0.81 (0.51 - 1.30) 0.39 1.86 (0.99 - 3.52) 0.06  ref  1.00 (0.65 - 1.54) 0.99 
TAC: tacrolimus, OR: odd ratio, CI: confidence interval 
P values were adjusted (when appropriate) for age of recipient at transplantation, sex of the recipient, hepatitis C status, baseline BMI, type of 
calcineurin inhibitor and type of donor. 
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Supplementary Table 5: Associations between CRTC2 rs1572788 T>C (in complete linkage 
disequilibrium (LD) with rs8450 G>A) and glycemic, lipidemic and obesity traits in several 
population-based samples: 
            Effect of each rs1572788 C-allele 
          (complete LD with rs8450 A-allele) 
phenotype n beta p-value Explained variance* 
     
Glucose£ 46186 0.01 0.004 0.0002 
     
2h glucose tolerance test£ 15234 -0.02 0.26  
     
HOMA-β£ 46186 -0.008 0.03 0.0001 
     
HOMA-IR£ 46186 0.0002 0.96  
     
Total cholesterol§ 97148 0.005 0.16  
     
HDL-Cholesterol§ 96908 -0.008 0.013 0.0001 
     
LDL-Cholesterol§ 92503 0.006 0.06  
     
Triglycerides§ 93562 0.009 0.004 0.0001 
     
BMI$ 113955 0.004 0.37  
     
Waist-hip ratio$ 55282 0.002 0.71  
     
Waist circumference$     
        Male 38305 0.008 0.32  
        Female 47320 0.01 0.19  
*explained variance by the polymorphism (only calculated for p<0.05). 
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£ This clinical variable was analyzed in the MAGIC study. 
§ This clinical variable was analyzed in the “Genome Wide Associations Scans for Total Cholesterol, HDL-
C, LDL-C and triglycerides”. 
$ This clinical variable was analyzed in the GIANT study. 
2h: 2 hours, HOMA: homeostatic model assessment, β: beta-cell function, IR: insulin resistance, BMI: Body 
mass index. 
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